Livzon Pharmaceutical (000513) investor relations material

Executive summary

• Revenue for H1 2025 was RMB 6.27 billion, down 0.17% year-over-year; net profit attributable to shareholders rose 9.40% to RMB 1.28 billion.

• Excluding non-recurring items, net profit attributable to shareholders increased 8.91% year-over-year.

• Cash flow from operations grew 10.26% year-over-year to RMB 1.69 billion.

• R&D investment reached RMB 491 million, representing 7.82% of total revenue.

• Key product lines in digestive, neuropsychiatric, reproductive, and TCM segments achieved year-over-year growth.

Financial highlights

• Gross margin for chemical formulations was 81.17%, up 0.02 percentage points year-over-year.

• Overseas revenue grew 18.40% year-over-year, accounting for 16.01% of total revenue.

• Net assets attributable to shareholders at period end were RMB 13.68 billion, down 1.33% from the start of the year.

• Basic and diluted EPS were both RMB 1.43, up from RMB 1.27 in the prior year.

• Operating cash flow margin improved, with cash and equivalents at RMB 10.35 billion.

Outlook and guidance

• Management expects continued focus on R&D, innovation, and international expansion.

• Ongoing product launches and pipeline advancement in key therapeutic areas are anticipated.

• The company is preparing for further regulatory and market changes, especially in reimbursement and procurement.